Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial.
Fiche publication
Date publication
octobre 2021
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr VERNEREY Dewi, Mme HENRIQUES Julie
Tous les auteurs :
Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, Vernerey D, André T, Laurent-Puig P
Lien Pubmed
Résumé
Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in the phase III IDEA-France trial.
Mots clés
Aged, Chemotherapy, Adjuvant, Circulating Tumor DNA, blood, Colonic Neoplasms, blood, Disease-Free Survival, Duration of Therapy, Female, Humans, Male, Neoplasm Staging, Prognosis, Prospective Studies
Référence
Clin Cancer Res. 2021 10 15;27(20):5638-5646